[JS03] Joint Session 03 (ASH-KSH): Chronic Myeloid Leukemia - Era of Next-Generation Sequencing
Room 1
March 28 (Fri), 09:00-10:15
Hawk Kim (Gachon University College of Medicine, Korea) Richard A. Van Etten (University of California, Irvine, USA)
09:00-09:15
Beyond BCR::ABL1 - the role of genomic analysis in the management of CML
Susan Branford (Centre for Cancer Biology, SA Pathology, Australia)
09:15-09:30
Next-generation sequencing (NGS) in CML
Jieun Kim (Soonchunhyang University College of Medicine, Korea)
09:30-09:45
What systems biology and AI can teach us about the pathogenesis and therapy of CML
Richard A. Van Etten (University of California, Irvine, USA)
09:45-10:00
Beyond BCR::ABL1 RQ-PCR in CML
Hawk Kim (Gachon University College of Medicine, Korea)
10:00-10:15
Discussion
[SS08] Scientific Session 08: TP53 Alterations in Hematological Malignancy: From Clonal Hematopoiesis to Acute Leukemia
Room 2
March 28 (Fri), 09:00-10:15
Sung-Hyun Kim (Dong-A University College of Medicine, Korea) Yoon Hwan Chang (Seoul National University College of Medicine, Korea)
09:00-09:25
Chronic inflammation as a driver of TP53-mutant leukemic evolution
Yan Liu (Northwestern University Feinberg School of Medicine, USA)
09:25-09:50
TP53 copy number and protein expression for risk stratification in AML
Joseph D. Khoury (University of Nebraska Medical Center, USA)
09:25-09:50
Molecular characterization of TP53 mutation in AML and high-risk MDS
Peter J.M. Valk (Erasmus University Medical Center, The Netherlands)
[SS09] Scientific Session 09: Advancing the Paradigm in Adult Acute Lymphoblastic Leukemia Care
Room 3
March 28 (Fri), 09:00-10:15
Seok Lee (Ewha Womans University College of Medicine, Korea) Ho-Young Yhim (Jeonbuk National University Medical School, Korea)
09:00-09:25
Advances in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: The emerging role of ponatinib and the shift away from allogeneic hematopoietic stem cell transplantation
Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
CAR T-cell therapy in relapsed/refractory acute lymphoblastic leukemia
Jae Park (Memorial Sloan Kettering Cancer Center, USA)
09:50-10:15
Navigating new horizons: Safety and efficacy of CD7-CAR-T cells in T-ALL/LBL
Yongxian Hu (The First Affiliated Hospital of College of Medicine, Zhejiang University, China)
Sangkyun Sohn (Kyungpook National University School of Medicine, Korea) Myungshin Kim (College of Medicine, The Catholic University of Korea, Korea)
09:00-09:25
MRD-based therapeutic decisions in AML
Dae Hun Kwag (College of Medicine, The Catholic University of Korea, Korea)
09:25-09:50
MRD-based therapeutic decisions in pediatric ALL
Jung Yoon Choi (Seoul National University College of Medicine, Korea)
09:50-10:15
MRD-based therapeutic decisions in MM
Ji Hyun Lee (Dong-A University College of Medicine, Korea)
[PL02] Plenary Lecture 02
Room 1+2
March 28 (Fri), 10:30-11:15
Sung-Soo Yoon (Seoul National University College of Medicine, Korea)
10:30-11:15
Evolutionary Legacy in Science and Clinical Medicine of Human CD38, a Catalytic Signaling Receptor
Fabio Malavasi (University of Torino, Italy)
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
12:15-13:05
Immunoglobulin Therapy in Immunocompromised Patients Undergoing SCT, CAR T-Cell, or Bispecific Antibody Treatment
Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
[SY06] Satellite Symposium 06: Johnson & Johnson Innovative Medicine
Room 2
March 28 (Fri), 12:15-13:05
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Reshaping Mantle Cell Lymphoma Treatment: Evidence from the Triangle and Sympatico Studies
Gyeong-Won Lee (Gyeongsang National University College of Medicine, Korea)
[SY07] Satellite Symposium 07: DKSH KOREA
Room 3
March 28 (Fri), 12:15-13:05
Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Romiplostim Across the Spectrum: A Comprehensive Analysis from ITP Management to Aplastic Anemia Treatment
Young Hoon Park (Ewha Womans University College of Medicine, Korea)
[SY08] Satellite Symposium 08: AbbVie Korea
Room 4
March 28 (Fri), 12:15-13:05
Seok Jin Kim (Sungkyunkwan University School of Medicine, Korea)
12:15-13:05
Real-World Evidence on How to Use Epcoritamab in 3L+ DLBCL
Georg Lenz (Munster University Hospital, Germany)
[SY09] Satellite Symposium 09: Novartis Korea
Room 5
March 28 (Fri), 12:15-13:05
Dong-Wook Kim (Eulji University School of Medicine, Korea)
12:15-13:05
Scemblix Experience in Post 2 TKI Setting and the Newly Diagnosed Setting
Michael J. Mauro (Memorial Sloan Kettering Cancer Center, USA)
Jeong A Kim (College of Medicine, The Catholic University of Korea, Korea) Kyung-Nam Koh (University of Ulsan College of Medicine, Korea)
13:35-13:47
Long-term treatment outcome of blinatumomab in adult patients with relapse or refractory acute lymphoblastic leukemia regarding predictive factors including lymphocyte kinetics for response and survival
Seonghan Lee (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Characteristics and treatment outcome of extramedullary relapse involving central nervous system after allogeneic hematopoietic cell transplantation in adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia
Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
13:59-14:11
Poor prognostic impact of TP53 mutation in association with CDKN2 and IKZF1 gene deletions in adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia
Seung-Hwan Lee (College of Medicine, The Catholic University of Korea, Korea)
14:11-14:23
Comparison of measurable residual disease results in adults with B-cell acute lymphoblastic leukemia according to the detection methods: Flow cytometry, NGS, and qPCR
Jae-Ho Yoon (College of Medicine, The Catholic University of Korea, Korea)
14:23-14:35
Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including three cases of MEF2D::DAZAP1 and a novel MEF2D-rearrangement
Senlin Zhang (Children’s Hospital of Soochow University, China)
14:35-14:47
Role of circulating immune cell signature in the persistence of measurable residual disease in adult B-cell lymphoblastic leukemia
Shraddha Mohanty (Advanced Centre for Treatment Research & Education in Cancer, Tata Memorial Centre, India)
[OP06] Oral Presentation 06: Others
Room 2
March 28 (Fri), 13:35-14:50
Jung Woo Han (Yonsei University College of Medicine, Korea) Sung-Eun Lee (College of Medicine, The Catholic University of Korea, Korea)
13:35-13:47
Comparison of eltrombopag vs romiplostim as salvage treatment in patients with relapsed/refractory aplastic anemia
Kyoung Il Min (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Eculizumab for transplant-associated thrombotic microangiopathy: A single-center pediatric experience
Hyun Jin Park (Seoul National University College of Medicine, Korea)
13:59-14:11
Investigating the first venous thromboembolism and recurrence pattern in inherited thrombophilia
Sang-A Kim (Seoul National University College of Medicine, Korea)
14:11-14:23
Letermovir prophylaxis for cytomegalovirus in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation
Qingwei Wang (Children's Hospital of Soochow University, China)
14:23-14:35
Clinical features and prognostic factors of adult systemic chronic active Epstein-Barr virus disease: A retrospective analysis using Japanese registry data
Hiroshi Yasui (St. Marianna University School of Medicine, Japan)
14:35-14:47
Clinical characteristics, genetic profiling, and outcomes of 108 patients with chronic myelomonocytic leukemia in a Southeast Asian country
Tarinee Rungjirajittranon (Faculty of Medicine Siriraj Hospital, Thailand)
Min Kyoung Kim (Yeungnam University College of Medicine, Korea) Ho Sup Lee (Kosin University College of Medicine, Korea)
13:35-13:47
Simulation-based comparative pharmacokinetic and pharmacodynamic analysis in real-world setting in Korean multiple myeloma patients: influence of demographic and ethnic differences [CAREMM-2109 study]
Suein Choi (College of Medicine, The Catholic University of Korea, Korea)
13:47-13:59
Molecular abnormalities in Waldenstrom’s macroglobulinemia patients treated with rituximab, bortezomib, lenalidomide and dexamethasone: Whole exome sequencing analysis in KMM1803 study
Ga-Young Song (Chonnam National University Medical School, Korea)
13:59-14:11
Toxicity-related treatment cessation in newly diagnosed multiple myeloma - risk factors and survival: An analysis from the APAC and ANZ myeloma and related diseases registry
Ji Hyun Lee (Dong-A University College of Medicine, Korea)
14:11-14:23
A phase II clinical study for evaluating the efficacy and safety of daratumumab, lenalidomide, bortezomib, and dexamethasone in transplantation-eligible elderly patients with newly diagnosed multiple myeloma (KMM2101)
Kihyun Kim (Sungkyunkwan University School of Medicine, Korea)
14:23-14:35
Korean multicenter real-world reports of patients with AL amyloidosis
Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea)
14:35-14:47
The burden of circulating tumor plasma cells is associated with quantity of mesenchymal stromal cells and CXCR4-expressing plasma cells in bone marrow of newly diagnosed multiple myeloma
Aravind Radhakrishnan (Post Graduate Institute of medical education and Research, India)
Byung Su Kim (College of Medicine, The Catholic University of Korea, Korea) Jae Wook Lee (College of Medicine, The Catholic University of Korea, Korea)
13:35-13:47
Enhanced efficacy and durability of AT101, a novel anti-CD19 CAR-T: Follow-up results from the phase 1 study in patients with relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma
Hyungwoo Cho (University of Ulsan College of Medicine, Korea)
13:47-13:59
Proteomic signatures and early predictive biomarkers of veno-occlusive disease in pediatric patients undergoing haploidentical HSCT with busulfan-based conditioning and post-transplant cyclophosphamide
Kyung Taek Hong (Seoul National University College of Medicine, Korea)
13:59-14:11
T cell profiling using LDA in pediatric haploidentical transplantation
Hyery Kim (University of Ulsan College of Medicine, Korea)
14:11-14:23
BCMA-specific T cell receptor (TCR)-T cells as a potential immunotherapy to treat patients with multiple myeloma
Jooeun Bae (Dana-Farber Cancer Institute, USA)
14:23-14:35
Study on immune haemolytic disease antibodies after haematopoietic stem cell transplantation
Jianyun Liao (Nanfang-Chunfu Children’s Institute of Hematology & Oncology, China)
14:35-14:47
The treatment efficacy and complications of allogeneic hematopoietic stem cell transplantation in children with inborn errors of immunity
Hui Zhang (Children’s Hospital of Soochow University, China)
Hyo Jung Kim (Hallym University College of Medicine, Korea) Ho-Jin Shin (Pusan National University School of Medicine, Korea)
15:05-15:30
Treatment strategies for transplant-eligible newly diagnosed multiple myeloma
Ja Min Byun (Seoul National University College of Medicine, Korea)
15:30-15:55
Treatment of transplant-ineligible multiple myeloma
Jongheon Jung (National Cancer Center, Korea)
15:55-16:20
Supportive care of multiple myeloma patients in the new agent era: Optimizing outcomes beyond therapy
Sung-Soo Park (College of Medicine, The Catholic University of Korea, Korea)
[SS10] Scientific Session 10: Next Steps toward Enhanced Treatment for Pediatric Lymphoid Malignancies
Room 2
March 28 (Fri), 15:05-16:20
Hyoung Jin Kang (Seoul National University College of Medicine, Korea) Keon Hee Yoo (Sungkyunkwan University School of Medicine, Korea)
15:05-15:30
Overcoming aggressive pediatric non-Hodgkin lymphoma
Birgit Burkhardt (University Hospital Münster, Germany)
15:30-15:55
Utilizing NGS MRD as an effective tool in ALL management
Yongmin Tang (Children’s Hospital of Zhejiang University School of Medicine, China)
15:55-16:20
CAEBV, from basic to updated therapeutic options
Seung Min Hahn (Yonsei University College of Medicine, Korea)
[SS11] Scientific Session 11: Driving the Future of our CAR
Room 3
March 28 (Fri), 15:05-16:20
Je-Jung Lee (Chonnam National University Medical School, Korea) Seok-Goo Cho (College of Medicine, The Catholic University of Korea, Korea)
15:05-15:30
Current status of "off-the-shelf" allogeneic CAR in the treatment of acute lymphoblastic leukemia
Reuben Benjamin (King’s College London, UK)
15:30-15:55
Allogeneic CAR-T cells engineered with gene-editing strategies for the treatment of B-cell non-Hodgkin lymphomas
Boyu Hu (University of Utah, USA)
15:55-16:20
Memory-like NK cells armed with a neoantigen-specific CAR
Rizwan Romee (Harvard Medical School, USA)
[ES06] Education Session 06: Patient Care in Cytopenia Consultations: Best Practices for Hematologists KORRoom 4
March 28 (Fri), 15:05-16:20
Deog-Yeon Jo (Chungnam National University College of Medicine, Korea) Chul Won Choi (Korea University College of Medicine, Korea)
15:05-15:30
Anemia
Eun sang Yu (Korea University College of Medicine, Korea)
15:30-15:55
Thrombocytopenia
Yoo Jin Lee (Ulsan University Hospital, Korea)
15:55-16:20
Neutropenia
Seonggyu Byeon (Gachon University College of Medicine, Korea)
[JS04] Joint Session 04 (Asia Session): Dawn of CAR-T Therapy: Asian Perspective
Room 1
March 28 (Fri), 16:35-17:50
Won Seog Kim (Sungkyunkwan University School of Medicine, Korea) William YK Hwang (National Cancer Centre Singapore, Singapore)
16:35-16:50
Current status of CAR-T treatment in Taiwan
Tai-Chung Huang (National Taiwan University Hospital, Taiwan)
16:50-17:05
Challenges and opportunities in CAR-T treatment in Singapore
William YK Hwang (National Cancer Centre Singapore, Singapore)
17:05-17:20
Developments of CAR-T cell therapy for multiple myeloma in China
Kailin Xu (The Affiliated Hospital of Xuzhou Medical University, China)
17:20-17:35
Present and future of CAR-T therapy in Korea
Dok Hyun Yoon (University of Ulsan College of Medicine, Korea)
17:35-17:50
Discussion
Myung Geun Shin (Chonnam National University Medical School, Korea) Seongsoo Jang (University of Ulsan College of Medicine, Korea)
16:35-17:00
Minimal (measurable) disease in hematologic malignancy
James L. Zehnder (Stanford University School of Medicine, USA)
17:00-17:25
Exploring the transcriptional and protein landscape of immune cells with CITE-seq
Jennifer A. Foltz (Washington University School of Medicine, USA)
17:25-17:50
Comprehensive resistance profiling of ABL1 variants against various kinase inhibitors using prime editing
Hyongbum Henry Kim (Yonsei University College of Medicine, Korea)
[SS13] Scientific Session 13: Innovations in Aplastic Anemia and Paroxysmal Nocturnal Hemoglobinuria
Room 3
March 28 (Fri), 16:35-17:50
Hoon Kook (Chonnam National University Medical School, Korea) Jun Ho Jang (Sungkyunkwan University School of Medicine, Korea)
16:35-17:00
Finding a better immunosuppressive treatment in SAA
Fengkui Zhang (Chinese Academy of Medical Sciences and Peking Union Medical College, China)
17:00-17:25
Alternative donor HSCT in SAA
Ho Joon Im (University of Ulsan College of Medicine, Korea)
17:25-17:50
Optimal treatment of PNH in the era of proximal complement inhibitors
Rosario Notaro (Core Research Laboratory, ISPRO, Italy)
Ki Seong Eom (College of Medicine, The Catholic University of Korea, Korea) Hyewon Lee (National Cancer Center, Korea)
16:35-17:00
Immunotherapy in follicular lymphoma
Gi June Min (College of Medicine, The Catholic University of Korea, Korea)
17:00-17:25
BTK inhibitions in Waldenström’s macroglobulinemia
Myung-won Lee (Chungnam National University College of Medicine, Korea)
17:25-17:50
Treatment for older patients with Hodgkin lymphoma
Hyunsoo Cho (Yonsei University College of Medicine, Korea)
